Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
NASDAQ:SPPI

Spectrum Pharmaceuticals - SPPI Stock Forecast, Price & News

$0.46
+0.03 (+7.66%)
(As of 11/25/2022 08:58 PM ET)
Add
Compare
Today's Range
$0.38
$0.48
50-Day Range
$0.38
$1.06
52-Week Range
$0.36
$1.81
Volume
4.22 million shs
Average Volume
3.62 million shs
Market Capitalization
$87.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Spectrum Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
548.5% Upside
$3.00 Price Target
Short Interest
Healthy
4.52% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
-0.59mentions of Spectrum Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.48) to ($0.27) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

585th out of 1,044 stocks

Pharmaceutical Preparations Industry

281st out of 510 stocks

SPPI stock logo

About Spectrum Pharmaceuticals (NASDAQ:SPPI) Stock

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.

Receive SPPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPPI Stock News Headlines

Spectrum Pharmaceuticals (NASDAQ:SPPI) Cut to Neutral at B. Riley
See More Headlines
Receive SPPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPPI Company Calendar

Last Earnings
11/10/2021
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/16/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SPPI
CUSIP
84763A10
Employees
163
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+548.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-158,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.29 per share

Miscellaneous

Free Float
183,084,000
Market Cap
$87.04 million
Optionable
Optionable
Beta
2.04

Social Links


Key Executives

  • Mr. Thomas J. RigaMr. Thomas J. Riga (Age 47)
    Pres, CEO & Director
    Comp: $1.02M
  • Ms. Nora E. Brennan (Age 53)
    Exec. VP & Chief Financial Officer
    Comp: $54.17k
  • Mr. Keith M. McGahan J.D.Mr. Keith M. McGahan J.D. (Age 46)
    L.L.M., Exec. VP, Chief Legal Officer & Corp. Sec.
    Comp: $851.73k
  • Dr. Francois J. Lebel FRCPC (Age 70)
    M.D., Exec. VP & Chief Medical Officer
    Comp: $917.96k
  • Mr. Bimal R. Shah
    VP of Corp. & Bus. Devel.
  • Dr. Lyndah K. Dreiling M.B.A.
    M.D., Sr. VP of Clinical Devel.













SPPI Stock - Frequently Asked Questions

Should I buy or sell Spectrum Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPPI shares.
View SPPI analyst ratings
or view top-rated stocks.

What is Spectrum Pharmaceuticals' stock price forecast for 2023?

4 brokerages have issued 12 month price objectives for Spectrum Pharmaceuticals' stock. Their SPPI share price forecasts range from $1.00 to $4.00. On average, they expect the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 548.5% from the stock's current price.
View analysts price targets for SPPI
or view top-rated stocks among Wall Street analysts.

How have SPPI shares performed in 2022?

Spectrum Pharmaceuticals' stock was trading at $1.27 at the beginning of 2022. Since then, SPPI stock has decreased by 63.6% and is now trading at $0.4626.
View the best growth stocks for 2022 here
.

When is Spectrum Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our SPPI earnings forecast
.

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) announced its quarterly earnings data on Wednesday, November, 10th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.07. During the same quarter in the prior year, the firm earned ($0.37) earnings per share.

What is Joseph Turgeon's approval rating as Spectrum Pharmaceuticals' CEO?

2 employees have rated Spectrum Pharmaceuticals Chief Executive Officer Joseph Turgeon on Glassdoor.com. Joseph Turgeon has an approval rating of 47% among the company's employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spectrum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE).

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (8.86%), Vanguard Group Inc. (4.61%), BlackRock Inc. (3.84%), Renaissance Technologies LLC (0.53%), CM Management LLC (0.43%) and State Street Corp (0.33%). Insiders that own company stock include Francois Lebel, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Nora Brennan, Seth H Z Fischer, Thomas J Riga and William Ashton.
View institutional ownership trends
.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $0.46.

How much money does Spectrum Pharmaceuticals make?

Spectrum Pharmaceuticals (NASDAQ:SPPI) has a market capitalization of $87.04 million. The biotechnology company earns $-158,630,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis.

How many employees does Spectrum Pharmaceuticals have?

The company employs 163 workers across the globe.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The official website for the company is www.sppirx.com. The biotechnology company can be reached via phone at (702) 835-6300, via email at ir@sppirx.com, or via fax at 702-260-7405.

This page (NASDAQ:SPPI) was last updated on 11/28/2022 by MarketBeat.com Staff